Research Site

Dothan, Alabama 36305

4 studies enrolling now · 25 studies all time

What they study most

Asthma, Bipolar Depression, Bipolar I Disorder, Breast Cancer, Early Breast Cancer, COPD, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disorder, Crohn's Disease, Dyspepsia, Healthy, Helicobacter Pylori Infection

Studies at this site

• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone — Completed
• Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms — Completed
• MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women — Completed
• Tezepelumab COPD Exacerbation Study — Completed
• Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma — Completed
• Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease — Stopped early
• Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma — Completed
• Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Completed
• Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) — Completed
• Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma — Completed
• ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator — Completed
• A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos) — Completed
• Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD — Completed
• Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease — Completed
• Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis — Completed
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History — Completed
• Pediatric Bipolar Depression — Completed
• Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder — Completed
• Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia — Completed
• An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants — Completed